Skip to main content
TipRanks
Go Ultimate75% OFF

NervGen Pharma (NGEN) Ratios

143 Followers

NervGen Pharma Ratios

NGEN's free cash flow for Q3 2026 was C$-12.81M. For the 2026 fiscal year, NGEN's free cash flow was increased by C$0.00 and operating cash flow was C$-12.81M. See a summary of the company’s cash flow.

Financial ratios
RatiosMar 26Mar 25Mar 24Dec 22Dec 21
Liquidity Ratios
Current Ratio1.161.120.832.2716.16
Quick Ratio1.161.120.832.2716.16
Cash Ratio1.121.020.772.2015.70
Solvency Ratio-2.23-1.41-1.46-1.73-11.69
Operating Cash Flow Ratio-0.99-1.00-0.75-1.74-7.67
Short-Term Operating Cash Flow Coverage0.00-173.200.000.000.00
Net Current Asset ValueC$ 3.07MC$ 2.10MC$ -2.73MC$ 12.73MC$ 16.34M
Leverage Ratios
Debt-to-Assets Ratio0.000.010.010.010.00
Debt-to-Equity Ratio0.000.04-0.100.020.00
Debt-to-Capital Ratio0.000.04-0.110.020.00
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio6.687.56-6.591.771.06
Debt Service Coverage Ratio0.00-246.030.00-33.960.00
Interest Coverage Ratio0.000.000.00-44.350.00
Debt to Market Cap0.000.000.000.000.00
Interest Debt Per Share0.000.000.000.020.00
Net Debt to EBITDA3.900.720.651.101.33
Profitability Margins
Gross Profit Margin0.00%0.00%0.00%0.00%0.00%
EBIT Margin0.00%0.00%0.00%0.00%0.00%
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
Operating Profit Margin0.00%0.00%0.00%0.00%0.00%
Pretax Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Profit Margin0.00%0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin0.00%0.00%0.00%0.00%0.00%
Net Income Per EBT100.00%100.00%100.00%87.38%99.33%
EBT Per EBIT175.91%96.29%125.91%90.79%98.91%
Return on Assets (ROA)-190.08%-123.19%-169.10%-75.84%-70.64%
Return on Equity (ROE)-1268.86%-931.69%1114.03%-134.51%-75.17%
Return on Capital Employed (ROCE)-721.31%-964.50%933.90%-167.10%-76.50%
Return on Invested Capital (ROIC)-719.57%-929.53%981.10%-145.09%-75.99%
Return on Tangible Assets-193.49%-126.21%-176.03%-77.23%-72.56%
Earnings Yield-7.94%-5.80%-13.98%-21.49%-11.79%
Efficiency Ratios
Receivables Turnover0.000.000.000.000.00
Payables Turnover0.000.000.260.060.12
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover0.000.000.000.000.00
Asset Turnover0.000.000.000.000.00
Working Capital Turnover Ratio0.000.000.000.000.00
Cash Conversion Cycle0.000.00-1385.46-6347.61-3018.80
Days of Sales Outstanding0.000.000.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding0.000.001385.466347.613018.80
Operating Cycle0.000.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-0.27-0.25-0.19-0.34-0.21
Free Cash Flow Per Share-0.27-0.25-0.19-0.34-0.21
Dividend Paid and CapEx Coverage Ratio0.000.00-79.88-842.65-183.41
Capital Expenditure Coverage Ratio0.000.00-79.88-842.65-183.41
Operating Cash Flow Coverage Ratio-2329.93-159.48-57.28-62.740.00
Operating Cash Flow to Sales Ratio0.000.000.000.000.00
Free Cash Flow Yield-3.51%-4.07%-7.14%-21.14%-7.75%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-12.60-17.06-7.15-4.65-8.48
Price-to-Sales (P/S) Ratio0.000.000.000.000.00
Price-to-Book (P/B) Ratio159.85160.55-79.686.266.38
Price-to-Free Cash Flow (P/FCF) Ratio-28.50-24.56-14.00-4.73-12.90
Price-to-Operating Cash Flow Ratio-28.50-24.56-14.17-4.74-12.97
Price-to-Earnings Growth (PEG) Ratio-0.186.31-0.61-0.740.99
Enterprise Value Multiple-94.43-16.58-8.43-3.09-7.07
Enterprise Value533.72M396.25M148.62M62.07M90.33M
EV to EBITDA-94.43-16.58-8.43-3.09-7.07
EV to Sales0.000.000.000.000.00
EV to Free Cash Flow-27.37-23.54-12.99-3.49-10.86
EV to Operating Cash Flow-27.37-23.54-13.16-3.49-10.92
Tangible Book Value Per Share0.040.03-0.040.250.42
Shareholders’ Equity Per Share0.050.04-0.030.260.43
Tax and Other Ratios
Effective Tax Rate0.000.000.000.130.01
Revenue Per Share0.000.000.000.000.00
Net Income Per Share-0.61-0.36-0.38-0.34-0.32
Tax Burden1.001.001.000.870.99
Interest Burden7.731.001.260.900.99
Research & Development to Revenue0.000.000.000.000.00
SG&A to Revenue0.000.000.000.000.00
Stock-Based Compensation to Revenue0.000.000.000.000.00
Income Quality0.440.700.500.860.65

Currency in CAD